Single-site, Open-label, Randomized, Cross-over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5mg/10cm2) Comparing Two Different Formulations.
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease; Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors UCB
- 02 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Feb 2010 New trial record